DIQTA 1.0: Drug-Induced QT Prolongation Atlas

ANGIOTENSIN II

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Ambiguous

Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

NONCLINICAL TOXICOLOGY
Safety Pharmacology
In a cardiovascular safety pharmacology study in normotensive dogs, GIAPREZA doses of 150, 450, and 1,800 ng/kg (5, 15, and 60 ng/kg/min) were infused intravenously for 30 minutes each. At ≥ 450 ng/kg, GIAPREZA caused significantly elevated MAP and systemic vascular resistance, as expected. The 1,800 ng/kg dose also caused increased heart rate, increased systemic vascular resistance, increased left ventricular systolic and end-diastolic pressures, and PR interval prolongation. GIAPREZA did not significantly alter respiratory rate or cause electrocardiographic changes in QRS duration or QTc.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24092

Other ADRs

122

38381465

Odds Ratio = 0.0

Drug Property Information

ATC Code(s):

C01CX09 - angiotensin ii

C01CX - Other cardiac stimulants
C01C - CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01 - CARDIAC THERAPY
C - CARDIOVASCULAR SYSTEM

Active Ingredient:ANGIOTENSIN II

Active Ingredient UNII:M089EFU921

Drugbank ID:DB11842

PubChem Compound:172198

CTD ID:D000804

PharmGKB:

CAS Number:4474-91-3

Dosage Form(s):injection

Route(s) Of Administrator:intravenous

Daily Dose:

Chemical Structure:

SMILE Code:
CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O

Reference

1: [Medication and comedication in COVID-19 patients].

[Lenkens M,de Wit H,Danser A H,Esselink A C,Horikx A,Ten Oever J,van de Veerdonk F,Kramers C]
Ned Tijdschr Geneeskd,2020 Mar 25;164:D4995. PMID: 32324352

2: Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

[Jin Sang-Man,Han Kyung Ah,Yu Jae Myung,Sohn Tae Seo,Choi Sung Hee,Chung Choon Hee,Park Ie Byung,Rhee Eun Jung,Baik Sei Hyun,Park Tae Sun,Lee In-Kyu,Ko Seung-Hyun,Hwang You-Cheol,Cha Bong Soo,Lee Hyoung Woo,Nam Moon-Suk,Lee Moon-Kyu]
Arterioscler Thromb Vasc Biol,2016 Oct;36(10):2108-14. PMID: 27493100

3: Kcne2 deletion creates a multisystem syndrome predisposing to sudden cardiac death.

[Hu Zhaoyang,Kant Ritu,Anand Marie,King Elizabeth C,Krogh-Madsen Trine,Christini David J,Abbott Geoffrey W]
Circ Cardiovasc Genet,2014 Feb;7(1):33-42. PMID: 24403551

4: Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease.

[Raizada Veena,Hillerson Dustin,Amaram Jaya Sheela,Skipper Betty]
J Investig Med,2012 Jun;60(5):785-91. PMID: 22481164

5: Ventricular arrhythmia risk after subarachnoid hemorrhage.

[Frangiskakis J Michael,Hravnak Marilyn,Crago Elizabeth A,Tanabe Masaki,Kip Kevin E,Gorcsan John,Horowitz Michael B,Kassam Amin B,London Barry]
Neurocrit Care,2009;10(3):287-94. PMID: 19184553

6: Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.

[Farkas A,Dempster J,Coker S J]
Br J Pharmacol,2008 Jul;154(5):958-70. PMID: 18587444

7: Cardiac-specific overexpression of the human type 1 angiotensin II receptor causes delayed repolarization.

[Rivard Katy,Paradis Pierre,Nemer Mona,Fiset Céline]
Cardiovasc Res,2008 Apr 1;78(1):53-62. PMID: 18245065

8: In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs.

[Wang Kai,Takahara Akira,Nakamura Yuji,Aonuma Kazutaka,Matsumoto Masahiko,Sugiyama Atsushi]
J Pharmacol Sci,2007 Feb;103(2):207-13. PMID: 17299243

9: Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation.

[Domenighetti Andrea A,Boixel Christophe,Cefai Daniel,Abriel Hugues,Pedrazzini Thierry]
J Mol Cell Cardiol,2007 Jan;42(1):63-70. PMID: 17070838

10: Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease.

[Raizada Veena,Skipper Betty,Luo Wentao,Garza Luis,Hines Curt W,Harford Antonia A,Zager Philip G,Griffith Jeffrey,Raj Dominic,Spalding Charles T]
Kidney Int,2005 Sep;68(3):1186-9. PMID: 16105049

11: Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog.

[Schoenmakers Marieke,Ramakers Christian,van Opstal Jurren M,Leunissen Jet D M,Londoño Camila,Vos Marc A]
Cardiovasc Res,2003 Aug 1;59(2):351-9. PMID: 12909318

Search for drugs: